StockNews.com Upgrades Compugen (NASDAQ:CGEN) to Buy

Compugen (NASDAQ:CGENGet Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

Separately, Truist Financial reduced their target price on Compugen from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday.

Get Our Latest Analysis on Compugen

Compugen Stock Up 25.8 %

Shares of NASDAQ CGEN opened at $2.34 on Tuesday. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03. The business has a 50 day moving average price of $2.23 and a two-hundred day moving average price of $1.88. The firm has a market cap of $202.69 million, a PE ratio of -12.32 and a beta of 2.72.

Compugen (NASDAQ:CGENGet Free Report) last issued its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $33.46 million for the quarter, compared to analyst estimates of $60.00 million. On average, analysts anticipate that Compugen will post 0.02 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Heron Bay Capital Management bought a new stake in shares of Compugen in the 1st quarter worth approximately $32,000. Tocqueville Asset Management L.P. bought a new stake in shares of Compugen in the 3rd quarter worth approximately $71,000. Kingsview Wealth Management LLC bought a new stake in shares of Compugen in the 3rd quarter worth approximately $78,000. Finally, Silverarc Capital Management LLC lifted its holdings in shares of Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

(Get Free Report)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Read More

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.